Respiratory syncytial virus infections and ribavirin treatment. Clinical and economic evaluation;L'emploi d'aerosols de ribavirine lors d'infection a virus respiratoire syncytial est-il justifie? Evaluation clinique et economique

Archives de Pediatrie

Volumn 5, Issue 2, 1998, Pages 123-131

  Ventura, F ^a   Cheseaux, J J ^a   Cotting, J ^a   Guignard, J P ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Evaluation studies; Respiratory syncitial viruses; Ribavirin

Indexed keywords

RIBAVIRIN; SALBUTAMOL; ANTIVIRUS AGENT;

ARTICLE; CHILD HOSPITALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SCREENING; FEMALE; HEALTH CARE COST; HEART DISEASE; HUMAN; IMMUNE DEFICIENCY; INFANT; INHALATIONAL DRUG ADMINISTRATION; LENGTH OF STAY; LUNG DISEASE; MALE; OXYGEN THERAPY; PATIENT SELECTION; PHYSIOTHERAPY; PREMATURITY; PRESCRIPTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK FACTOR; RNA VIRUS INFECTION; AEROSOL; ARTIFICIAL VENTILATION; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; COST; ECONOMICS; FRANCE; MULTICENTER STUDY; NEWBORN; VIRUS INFECTION;

AEROSOLS; ALBUTEROL; ANTIVIRAL AGENTS; COHORT STUDIES; COSTS AND COST ANALYSIS; FEMALE; FRANCE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY THERAPY; RIBAVIRIN; RISK FACTORS;

EID: 0032006129     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(97)86824-8     Document Type: Article

References (48)

1. 1 Hall CB. Respiratory syncytial virus. In: Feigin RD, Cherry JD, eds. Textbook of Pediatrics Infectious Diseases. 2nd ed. Philadelphie: WB Saunders; 1987. p 1653-76
2. 2 McIntosh K, Chanock RM. Respiratory syncytial virus. In: Fields BN, Knipe DM, eds. Virology. 2nd ed. New York: Raven Press Ltd; 1990. p 1045-72
3. 3 Mac Donald NE, Hall CB, Suffin SC. Alexson C, Harris PJ. Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982 ; 307 : 397-400
4. 4 Moler FW, Khan AS, Meliones JN, Custer JR, Palmisano J, Shope TC. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit Care Med 1992 ; 20 : 1406-13
5. 5 Meert K, Heidemann S. Lieh-Lai M, Sarnaik AP. Clinical characteristics of respiratory syncytial virus infection in healthy versus previously compromised host. Pediatr Pulmonol 1989 ; 7:167-70
6. 6 Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988 ; 82 : 199-203
7. 7 Meert K, Heidemann S, Abella B, Sarnaik A. Does prematurity alter the course of respiratory syncytial virus infection. Crit Care Med 1990 ; 18 : 1357-9
8. 8 Hall CB, Powell KR, MacDonald NE et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 1986 ; 315 : 77-81
9. 9 McIntosh K, Kurachek SC, Cairns LM, Burns LC, Goodspeed. Treatment of respiratory viral infection in an immunodeficient infant with ribavirin aerosol. Am J Dis Child 1984 ; 138 : 305-8
10. 10 Hall CB, McBride JT, Walsh EE et al. Aerolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med 1983 ; 308 : 1443-7
11. 11 Taber LH, Knight V, Gilbert BE et al. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics 1983 ; 72 : 613-8
12. 12 Hall CB, McBride JT, Gala CL, Hildreth SW, Schnabel KC. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA 1985 ; 254 : 3047-51
13. 13 Rodriguez WJ, Kim HW, Brandt CD et al. Aerolized ribavirin in the treatment of patients with respiratory syncytial virus disease. Pediatr Infect Dis J 1987 ; 6 : 159-63
14. 14 Brunel PA, Daum RS, Giebink GS et al, Committee on Infectious Diseases. Ribavirin therapy of respiratory syncytial virus. Pediatrics 1987 ; 79 : 475-8
15. 15 Wald ER, Dashefsky B, Green M. In re ribavirin: a case of premature adjudication? J Pediatr 1988 ; 112 : 154-8
16. 16 Dashefsky B, Wald ER, Green M. Ribavirin use questioned. Pediatrics 1988 ; 82 : 283-4
17. 17 Isaacs D, Moxon ER, Harvey D el al. Ribavirin in respiratory syncytial virus infection. A double blind placebo controlled trial is needed. Arch Dis Child 1988 ; 63 : 986-90
18. 18 Ray CG. Ribavirin : Ambivalence about an antiviral agent. Am J Dis Child 1988; 142 : 488-9
19. 19 Wheeler JG, Wofford J, Turner RB. Historical cohort evaluation of ribavirin efficacy in Respiratory Syncytial Virus infection. Pediatr Infect Dis J 1993 ; 12 : 209-13
20. 20 Hall CB, Granoff DM, GromiSch DS et al, Committee on Infectious Diseases. Use of ribavirin in the treatment of respiratory syncytial virus infection. Pediatrics 1993 ; 92 : 501-4
21. 21 Rodriguez WJ, Dang Bui RH, Connor JD et al. Environmental exposure of primary care personnel to ribavirin aerosol when supervising treatment of infants with respiratory syncytial virus infections. Antimicrob Agents Chemother 1987 ; 31 : 1143-6
22. 22 McMillan JA, Tristram DA, Weiner LB, Higgins AP, Sandstrom C, Brandon R. Prediction of the duration of hospitalization in patients with respiratory syncytial viral infection : use of clinical parameters. Pediatrics 1988 ; 81 : 22-6
23. 23 Kuzel RJ, Clutter DJ. Current perspectives on respiratory syncytial virus infection. Postgrad Med 1993 ; 93 : 129-32, 137-8, 141
24. 24 Nahata MC, Schad PA. Pattern of drug usage in bronchiolitis. J Clin Pharm Ther 1994 ; 19 : 117-8
25. 25 Hendry RM, Pierik LT, McIntosh K. Prevalence of respiratory syncytial virus subgroups over six consecutive outbreaks 1981-1987. J Infect Dis 1989 ; 160 : 185-90
26. 26 McIntosh K, Pierik L, Hendry RM. Virulence of the two major antigenic subgroups of respiratory syncytial virus in hospitalized infants [Abstract]. Pediatr Res 1988 ; 23 : 292A
27. 27 Brouard J, Freymuth F, Constantini S, Petitjean F, de Schrevel G, Duhamel JF. Prevalence and clinical aspect of A and B subgroups of respiratory syncytial virus infection. Observation of 8 consecutive epidemics between 1982 and 1990. Arch Fr Pédiatr 1993 ; 50 : 639-43
28. 28 McIntosh ED, De Silva LM, Oates RK. Clinical severity of respiratory syncytial virus group A and group B infection in Sydney. Australia. Pediatr Infect Dis J 1993 ; 12 : 815-9
29. 29 Marks MI, Hall CB. Red Book recommendations on ribavirin challenged [letter|. Pediatrics 1994 ; 93 : 873-4
30. 30 Zucker AR. Red Book recommendations on ribavirin challenged [letter]. Pediatrics 1994 ; 93 : 872-3
31. 31 Baraldi E, Zanconato S, Rebeschini G, Biban P, Donzelli F, Da Dale L. Aerosolised ribavirin in the treatment of bronchiolitis due to RSV. Ital J Pediatr 1987 ; 13 : 19-20
32. 32 Barry W, Cockburn F, Cornall R, Price JF, Sutherland G, Vardag A. Ribavirin aerosol for acute bronchiolitis. Arch Dis Child 1986 ; 61 : 593-7
33. 33 Caramia G, Palazzini E. Efficacy of ribavirin aerosol treatment for respiratory syncytial virus bronchiolitis in infants, J Int Med Res 1987 ; 15 : 227-33
34. 34 Conrad DA, Christenson JC, Waner JL, Marks MI. Aerolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic. Pediatr Infect Dis J 1987 ; 6 : 152-8
35. 35 Solli R, Sartori B. Trattamento dell'infezione da virus respiratorio sincizlale. Impego di un nuovo farmaco antivirale per aerosol. G Ital Pediatrico 1988 ; 9 : 151
36. 36 Englund JA, Piedra PA, Jefferson LS, Wilson SZ, Taber LH, Gilbert BE. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. J Pediatr 1990 : 117 : 313-20
37. 37 Hiatt P, Treece D, Tubr L. Pulmonary function following treatment with ribavirin in infants hospitalized with RSV bronchiolitis. Am Rev Respir Dis 1990 ; 141 : A624
38. 38 Groothuis JR, Woodin KA, Katz R, et al. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. J Pediatr 1990 ; 117 : 792-8
39. 39 Frankel LR, Wilson CW, Demers RR, et al. A technique for the administration of ribavirin to mechanically ventilated infants with severe respiratory syncytial virus infection. Crit Care Med 1987 ; 15 : 1051-4
40. 40 Edelson PJ. Clinical studies with ribavirin. Pediatr infect Dis J 1990 ; 9 : 71-3
41. 41 Smith CM, Anderson SD. Inhalation provocation tests using nonisotonic aerosols. J Allergy Clin Immunol 1989 ; 84 : 781-90
42. 42 Caspey LJ, Jones KL, Snell NJC. Safety and tolerance of nebulised ribavirin in clinical usage. Acta Therapeutica 1992 ; 18 : 133-47
43. 43 Eisenberg J. Hemodynamic alterations in patients treated with ribavirin. Pediatr Infect Dis J 1990 ; 9 : S93-4
44. 44 Janai HK, Stutman HR, Zaleska M et al. Ribavirin effect on pulmonary function in young infants with respiratory syncytial virus bronchiolitis. Pediatr Infect Dis J 1993 ; 12 : 214-8
45. 45 Pollack MM. An RSVP to RSV (respiratory syncytial virus): Declining mortality rates. Crit Care Med 1992 ; 20 : 1375-6
46. 46 Smith DW, Frankel LR, Mathers LH, Tang AT, Ariagno RL, Prober CG. A controlled trial of aerolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991 ; 325 : 24-9
47. 47 Meert KL, Sarnaik AP, Gelmini MJ, Lieh-Lai MW. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease : A prospective, double-blind, randomized trial. Crit Care Med 1994 ; 22 : 566-72
48. 48 Wald ER, Dashefsky B. Ribavirin. Red Book Committee recommendations questionned. Pediatrics 1994 ; 93 : 672-3